TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW)

Abstract

The relevance of the presented review is due to the high incidence of type 1 neurofibromatosis (NF1) and type 2 neurofibromatosis (NF2) in the population and frequent association with the development of malignant neoplasms. The purpose of the review is to analyze literature data that describe the results of the use of targeted drugs for the treatment of neoplasms in patients with neurofibromatosis. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. Data on pharmacogenetics and the principles of etiopathogenetic therapy with the use of the following targeted therapy are presented: bevacizumab, erlotinib, imatinib, sorafenib, sirolimus. The summary table with the results of the survey contains information from 39 literature sources. According to the majority of authors, innovative target therapy of neurofibromatosis can be effective in many patients with advanced forms of the disease.

Keywords

• нейрофиброматоз
• NF1
• NF2
• таргетная терапия